

From the Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom.

1. Cummings JL. Alzheimer's disease. *N Engl J Med* 2004;351:56-67.
2. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B₁₂, and serum total homocysteine levels in confirmed Alzheimer disease. *Arch Neurol* 1998;55:1449-55.
3. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med* 1991;324:1149-55.
4. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002;346:476-83.
5. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. *Ann Neurol* 2002;51:285-9.
6. den Heijer T, Vermeer S, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. *Brain* 2003;126:170-5.
7. Prins ND, Den Heijer T, Hofman A, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. *Neurology* 2002;59:1375-80.
8. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocys-

teine: a meta-analysis of the randomized trials. *Am J Clin Nutr* 2005;82:806-12.

9. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. *N Engl J Med* 2006;354:2764-72.
 10. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. *Am Heart J* 2006;151:282-7.
 11. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. *Am J Clin Nutr* 2005;82:442-50.
 12. Morris MC, Evans DA, Bienias JL, et al. Dietary folate and vitamin B₁₂ intake and cognitive decline among community-dwelling older persons. *Arch Neurol* 2005;62:641-5.
 13. Clarke R, Grimley Evans J, Schneede J, et al. Vitamin B₁₂ and folate deficiency in later life. *Age Ageing* 2004;33:34-41.
 14. Hin H, Clarke R, Sherliker P, et al. Clinical relevance of low serum vitamin B₁₂ concentrations in older people: Banbury B₁₂ Study. *Age Ageing* 2006;35:416-22.
 15. Department of Health. Folate and disease prevention. London: Scientific Advisory Committee on Nutrition, 2006.
- Copyright © 2006 Massachusetts Medical Society.

Iodine Nutrition — More Is Better

Robert D. Utiger, M.D.


In normal adults, the daily production rate of the two biologically active thyroid hormones, tetraiodothyronine (which is better known as thyroxine and has four iodine atoms) and triiodothyronine (which has three), is approximately 100 μg and 30 μg , respectively. All of the thyroxine, but only about 20 percent of the triiodothyronine, is produced by the thyroid gland; the remainder of the triiodothyronine is produced through the extrathyroidal deiodination of thyroxine. A minimum of approximately 70 μg of iodine is therefore needed to produce these two hormones in the thyroid gland each day. But more than that is required, because iodine — whether ingested, released from the thyroid when the iodotyrosine precursors of the hormones are deiodinated, or released when the hormones are deiodinated in extrathyroidal tissues — is rapidly excreted in the urine. Infants, children, and pregnant or lactating women need more iodine, because their thyroxine production rate is relatively high.

The World Health Organization (WHO) has recommended that children 5 years of age or younger ingest 90 μg of iodine daily; children 6 to 12 years of age, 120 μg daily; adults, 150 μg daily; and pregnant or lactating women, 200 μg daily.¹ The prediction of iodine intake is difficult,

if not impossible, because the amount of iodine in individual foods and in water can vary by a factor of 100.^{2,3} The standard measure of iodine nutrition in a community or country is the median urinary iodine excretion, expressed in micrograms per liter. The values correspond to 70 to 80 percent of the daily iodine intake, which often varies widely among people in the same community or country.

Iodine can come only from external sources — mostly food, but also water. It is not widely distributed in nature; in the past, iodine deficiency was common among people on every continent. Many people are still deficient in iodine, despite major national and international efforts to increase iodine intake, primarily through the voluntary or mandatory iodination of salt. Indeed, in some countries, even salt for animals is iodinated. These efforts have been successful in many countries. However, iodine deficiency persists in many other countries (e.g., Australia, Russia, and some countries in Africa and Europe) (Fig. 1). The WHO estimates that approximately 2 billion people, including 285 million school-age children, still have iodine deficiency, defined as a urinary iodine excretion of less than 100 μg per liter.

An increase in iodine intake is only the first



step in the amelioration of iodine deficiency. The increase must be sustained, which has not always been the case. In the United States, where salt iodination is not mandatory but iodized salt (45 to 80 μg of iodine per gram of salt) is used in about 70 percent of households, the median urinary iodine excretion in adults declined from 320 μg per liter in 1971–1974 to 145 μg per liter in 1988–1994; and it was 168 μg per liter in 2001–2002.^{5,6} Among pregnant women, the frequency of moderate iodine deficiency (urinary iodine excretion of less than 50 μg per liter) was 1 percent in 1971–1974 and 7 percent in both 1988–1994 and 2001–2002.^{5,6} (According to the WHO, a median urinary iodine excretion of 100 to 199 μg per liter indicates that the iodine intake is adequate, but the U.S. data above suggest strongly that it should be considered marginal.) The causes of the decline include reduced salt intake and the reduced use of iodate in baking and iodine in animal husbandry, as well as the use of noniodized salt in processed foods. Iodine intake has also diminished in other countries — such as Australia, Guatemala, and Morocco — for similar reasons or because the iodination of salt was not monitored adequately or ceased.

What are the consequences of iodine deficiency and excess? The spectrum of chronic iodine-deficiency disorders is broad. Severe iodine deficiency in mothers and fetuses results in preg-

nancy loss and cretinism, with irreversible mental retardation, neurologic dysfunction, and growth retardation. Mild iodine deficiency results in learning disability, poor growth, and diffuse goiter in school-age children. These consequences of mild deficiency are easily understood — the production of thyroid hormones is reduced, and the thyroid gland enlarges to compensate for the reduction. In adults, mild iodine deficiency is also associated with nontoxic nodular goiter and, less often, with toxic nodular goiter, because the constitutive (thyrotropin-independent) growth and functional potential of some clones of thyroid cells increases.

The spectrum of disorders of iodine excess also includes hypothyroidism and hyperthyroidism. Milligram or higher doses of iodine may cause hypothyroidism in people with damaged thyroid glands and normalization of thyroid secretion in those with hyperthyroidism. This antithyroid action of iodine is often short-lived, owing to down-regulation of iodine transport into the thyroid gland, but such down-regulation does not occur in people with a damaged thyroid gland. Conversely, iodine in these quantities may induce hyperthyroidism in patients with a multinodular goiter or Graves' disease whose iodine intake is low, although it is unlikely to do so if the deficiency is not severe and if the increase in intake is relatively small.

A more important issue is whether some level of chronic iodine intake is harmful. Some classifications of iodine nutrition include categories of high or excessive iodine intake, because high levels of iodine intake have sometimes been associated with an increased risk of hyperthyroidism, hypothyroidism, or autoimmune thyroiditis. Indeed, fear of iodine-induced thyroid dysfunction has at times delayed or limited the implementation of iodine supplementation in regions with iodine deficiency. The divergent effects of such supplementation on thyroid disorders may be related to underlying thyroid autonomy or genetic susceptibility to the disorders. The evidence for these increased risks is based largely on the results of cross-sectional studies before and after iodine intake increased.

In this issue of the *Journal*, Teng et al.⁷ provide new data on these risks. They studied people living in three regions of China in whom iodine intake was mildly deficient, more than adequate, or excessive (as defined by Teng et al.) and remained so for five years. The investigators found that more than adequate or excessive iodine intake was associated with a slightly increased cumulative five-year incidence of subclinical hypothyroidism and autoimmune thyroiditis, but not of overt hypothyroidism or hyperthyroidism. In many people, the first two disorders — both of uncertain clinical importance — were not sustained.

Overall, the small risks of chronic iodine excess are outweighed by the substantial hazards of iodine deficiency, which is still widespread. All these hazards — pregnancy loss, goiter, and mental retardation — are prevented by an adequate

iodine intake. To achieve this, iodine intake should be increased in most countries, not only in those with iodine deficiency but also in those whose iodine intake is marginal, so the iodine intake is at least 300 to 400 μg daily. An increased intake is especially important for children and pregnant or lactating women. Given the highly variable iodine content of food and water, the best way to increase iodine intake is to increase the iodination of salt and to make salt iodination mandatory in most countries. Then, even mild iodine deficiency should be very rare.

No potential conflict of interest relevant to this article was reported.

From the Department of Medicine, Brigham and Women's Hospital, Boston.

1. WHO global database on iodine deficiency. Geneva: World Health Organization. (Accessed June 8, 2006, at <http://www3.who.int/whosis/micronutrient>.)
2. Pearce EN, Pino S, He X, Bazrafshan HR, Lee SL, Braverman LE. Sources of dietary iodine: bread, cows' milk, and infant formula in the Boston area. *J Clin Endocrinol Metab* 2004;89:3421-4.
3. Pedersen KM, Laurberg P, Nøhr S, Jørgensen A, Andersen S. Iodine in drinking water varies by more than 100-fold in Denmark: importance for iodine content of infant formulas. *Eur J Endocrinol* 1999;140:400-3.
4. de Benoist B, Andersson M, Egli I, Takkouche B, Allen H, eds. Iodine status worldwide: WHO global database on iodine deficiency. Geneva: World Health Organization, 2004.
5. Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States: trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). *J Clin Endocrinol Metab* 1998;83:3401-8.
6. Caldwell KL, Jones R, Hollowell JG. Urinary iodine concentration: United States National Health and Nutrition Examination Survey 2001-2002. *Thyroid* 2005;15:692-9.
7. Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. *N Engl J Med* 2006;354:2783-93.

Copyright © 2006 Massachusetts Medical Society.

CLINICAL TRIAL REGISTRATION

The *Journal* encourages investigators to register their clinical trials in a public trials registry. The members of the International Committee of Medical Journal Editors plan to consider clinical trials for publication only if they have been registered (see *N Engl J Med* 2004;351:1250-1). The National Library of Medicine's www.clinicaltrials.gov is a free registry, open to all investigators, that meets the committee's requirements.